Skip to content
PACLITAXEL Injection, USP Print E-mail
Innovator Product Name:TAXOL® (TAXOL is a registered trademark of Bristol-Myers Squibb Company)  Electronic Catalog
Therapeutic Category: Antineoplastic Agent

  • Consider these SAGENT Benefits:
  • • Available in
  •   - 30 mg per 5 mL multi-dose vials
      - 100 mg per 16.7 mL multi-dose vials
  •   - 300 mg per 50 mL multi-dose vials
  • • Preservative-free
  • • Discover PreventIV MeasuresSM packaging features:
  •   - Easy-to-read drug name and dosage strength to aid in identifying the right product
  •   - Bar codes included on the vial and carton for ease of scanning
  •   - Unique label design to help products stand out on the shelf
  •   - Enhanced packaging and labeling designed to promote safety and help reduce medication errors
NDC #25021
Description Strength Fill Volume Concentration
Container Size Closure Unit of Sale
Package Insert Storage Requirements Product Photos 360o View
213-05 Glass Vial 30 mg 5 mL
6 mg per mL
8 mL 20 mm 1 Package Insert Package Insert
Product Photos 360 Product View
213-17 Glass Vial 100 mg 16.7 mL
6 mg per mL
20 mL 20 mm
1 Package Insert Package Insert
Product Photos 360 Product View
Glass Vial 300 mg
50 mL
6 mg per mL
50 mL
20 mm
1 Package Insert Storage Requirements
Product Photos 360 Product View
Paclitaxel Catalog Insert    MSDS Sheet    Bar Codes    Wholesaler Item Numbers
PACLITAXEL Injection, USP should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.
Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2 to 4% of patients receiving paclitaxel in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H2  antagonists. (See DOSAGE AND ADMINISTRATION.) Patients who experience severe hypersensitivity reactions to paclitaxel should not be rechallenged with the drug.
PACLITAXEL Injection, USP therapy should not be given to patients with solid tumors who have baseline neutrophil counts of less than 1500 cells/mm3 and should not be given to patients with AIDS-related Kaposi’s sarcoma if the baseline neutrophil count is less than 1000 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving PACLITAXEL Injection, USP.
   Please refer to full prescribing information and medication guide.

 [Back to Products page]
LATEX-FREE = There is no natural rubber latex in the vial container closure or label adhesive in this SAGENT product.
This product information is intended for U.S. residents only.  All trademarks and registered trademarks are the property of their respective owners.